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Vaccine Technologies
• Advancing technologies to improve vaccine 
performance and delivery.
Vaccine Technologies:
Three Areas of Focus
• Cold chain technologies
• Delivery technologies
• Formulation and stabilization technologies
Introduction
• For more than a decade, PATH has been exploring 
both the technical and commercial feasibility of 
stabilizing vaccines for use in developing countries.
• To date, we have conducted research on 7 antigen 
types with 11 vaccine producers and 22 technical 
collaborators.
• This presentation will summarize lessons learned over 
the past 10 years.
• Funding: Bill & Melinda Gates Foundation.
Kristensen D. Chen D. Stabilization of vaccines: Lessons learned. Human 
Vaccines. 2010;6:229-231.
Stability Profile of Current Vaccines
Vaccines
Lesson 1: Integrate stabilization 
efforts into early vaccine 
development.
Integrate Stabilization Efforts Early
• Once a vaccine has an established record of safety 
and clinical efficacy, there are risks and costs 
associated with reformulation.
• Improvements in vaccine stability will almost always 
be less expensive during initial vaccine development 
than after regulatory approval.
Lesson 2: There are circumstances 
where it makes sense to stabilize 
existing vaccines.
Stabilizing Existing Vaccines Can Make 
Sense When:
• Stability of the product is unacceptable or inferior to 
other marketed products, e.g., requires frozen storage.
• Reformulation is needed for other reasons, e.g., a 
change in antigen concentration or production process 
or inclusion of an additional antigen.
• Proof of principle is needed for a new stabilization 
method. New technologies are easier to assess and 
demonstrate with an established vaccine.
Lesson 3: Freeze stabilization is 
possible for vaccines containing 
aluminum adjuvants.
Freeze Sensitivity of Vaccines
• Aluminum salt adjuvants are the most prevalent 
adjuvants in human vaccines.
• Aluminum adjuvants irreversibly agglomerate when 
frozen then thawed, reducing vaccine potency. 
• There are several causes of accidental freezing, e.g.:
– malfunctioning or inappropriate refrigeration equipment
– use of cold packs during shipping that are frozen before 
use
– low ambient temperatures during shipping
Freeze Sensitivity of Vaccines
• Losses due to freeze damage stress already 
underfunded vaccine programs in developing 
countries.
US CDC estimates that the federal 
Vaccines for Children program 
alone incurs more than $20 million 
in vaccine waste annually from 
accidental freezing.
Meta-Analysis of Vaccine Exposure to 
Freezing Underscores Problem and Need
• Meta-analysis of 33 studies (Matthias, et al, Vaccine. 2007;25:3980-3986).
• 14% to 35% of vaccines were exposed to freezing temperatures.
• More rigorous study designs detected more freeze damage.
Cold Chain Temperature Studies:











Indonesia 50% 25% 75%
Vietnam 63% 50% 100%
Bolivia 100% 60% 100%
Mozambique 75% 80% 100%
Protecting Vaccines From Freeze Damage
• Aluminum adjuvant-containing vaccines can be 
protected from freeze damage by inclusion of GRAS 
excipients (propylene glycol, polyethylene glycol 300, 
or glycerin). 
• PATH and collaborators have validated protection with 
hepatitis B, DTP, and pentavalent (DTP-hepatitis B-
Hib) vaccines.
Freeze Stabilization of Hepatitis B Vaccine
Immunogenicity of vaccine samples in mice following storage at 
4°C or three -20 C/room temperature freeze-thaw cycles, with 
and without freeze-protecting excipients.
Jones Braun, et al. Vaccine. 2009; 27:72–79.
Vaccine Freeze-Protection Technology 
Is Available to All Companies
• PATH estimates freeze-protecting excipients (e.g., 
propylene glycol) add only US$0.001 of cost per dose.
• Two vaccine producers are incorporating the freeze-
protection technology into childhood vaccines.
• PATH has placed the freeze-protection technology in 
the public domain for use without charge by all vaccine 
producers.
• Freeze protection should be considered for all new 
alum-adjuvanted vaccines.
• PATH staff are available to provide information and 
assistance.
Lesson 4: Heat stabilization requires 
a more customized approach, and 
results will be variable.
Example 1: Heat- and Freeze-Stable Liquid 




























Commercial Hep B vaccine Stable Hep B vaccine formulation
Phosphate, saline Phosphate, histidine, and propylene glycol
pH 7.0 pH 5.2
Jones Braun, et al. Vaccine. 2009;27:4609-4614.
Example 2: Spray-Dried Measles Vaccine 
• Most commercial lyophilized measles products lose 
greater than 1 log10 virus titer within one week of 
storage at 37 C (exception is GSK’s Rimevax).
• PATH and our collaborators have shown that spray 
drying of measles vaccine has a lower process loss 
than freeze drying or foam drying.
• Spray drying process parameters, residual moisture, 
pH, surfactants, excipients, and divalent cations used 
were systematically examined for effect on process 
loss and storage stability.
Example 2: Spray Dried Measles Vaccine:
8 weeks stability at 37 C
• Result: The optimized spray-dried formulation 
exhibited a loss of 0.9 log TCID50 at 37 C in 8 weeks. 
• Best-performing formulation: 17% w/v trehalose-
sucrose; 50 mM KPO4, 4% w/v L-arginine; 1.25% wt. 
glycerol; 4% w/v human serum albumin; 1-4 mM 
CaCl2; 1-4 mM ZnCl2; pH 6.0.  
• Bottom line: This is a meaningful improvement in 
stability over some commercial freeze-dried measles 
products, but only an incremental improvement in 
stability over Rimevax (time to 1 log10 loss = 5 weeks).
Ohtake, et al. Vaccine. 2010;28:1275-1284.
Lesson 5: The full benefits of heat-
stable vaccines will only be realized 
after changes are made to storage 
guidelines.
Cold chain storage in an Asian country - WHO
Controlled Temperature Chain
• All vaccines should be kept in a controlled temperature 
chain (CTC). 
– Traditionally, this has been the +2 C to +8oC range, known as 
the cold chain.
– Work is underway to label some products for higher temperature 
storage.
• Many vaccines are quite heat stable. 
– Could be stored safely above 2 C to 8 C in CTC.
– Storage guidelines need to be appropriate to the vaccine's heat 
stability profile.
– Vaccine vial monitors can be used to help ensure against 
excessive heat exposure. 
Precedents Exist for Vaccines To Be Stored 
at Controlled Room Temperature
• NeisVac-C® Meningococcal C Vaccine - Baxter, under 
license to GSK - Canadian product insert:
– Store at 2°C to 8°C. 
– Within the indicated shelf life the product may be stored at 
room temperature (up to +25°C) for a single period not 
exceeding 9 months.
• Dukoral® Cholera Vaccine - Sanofi Pasteur - Canadian 
product insert: 
– Store at 2°C to 8°C.
– The vaccine can be stored at room temperature (<27°C) for 
up to 2 weeks on one occasion only.
Experience Using Vaccines 
Outside of Refrigerated Storage
• Multiple studies have reported that hepatitis B vaccine 
used for birth dose can be stored outside of 
refrigerated storage with no effect on seroconversion 
rates.  (Data from China, Indonesia, and Vietnam.) 
Wang, et al. Bull. World Health Org. 2007;85:649-732.
Sutanto, et al. Bull. World Health Org. 1999;77:119-126.
Hipgrave, et al. Journal Trop. Med. and Hygiene. 2006;74:225-260.  
• Meningococcal group C vaccines have been stored at 
controlled room temperature for 6 months prior to 
administration, with no effect on immune response.
Schondorf, et al. Vaccine. 2007;25:1175-1182.  
Four Steams of Work Needed for Success 
COUNTRY-LEVEL EVIDENCE
- Identifying strategies and conditions 
where ambient temperature storage 
makes sense.
CHANGES TO STORAGE 
GUIDELINES
- Working to license vaccines, esp. new 








- Vaccine vial monitors (VVM), 
threshold heat indicators, electronic 
temperature monitors.
Preferred Product Profile for Vaccines
• Developed by the Vaccine Presentation and Packaging 
Advisory Group (VPPAG) - led by WHO with input from 
public health entities, nonprofits, governments agencies, and 
industry.
• Among the recommendations in VPPAG’s new Preferred 
Product Profile:
- Maximize heat and freeze stability.
- License products for higher-
temperature storage.
* VPPAG membership includes GAVI, PATH, UNICEF 
Supply Division and Programme Division, WHO 
Expanded Programme on Immunization, US CDC,  
among many others.
Lesson 6: Trade-offs may need to be 
made between the heat stability and 
the format characteristics of a 
vaccine.
Heat Stability vs. Vaccine Format
• Some heat stability improvements result in suboptimal 
product formats, while others enable new, beneficial 
formats.  
• Trade-off between stability and other attributes may be 
encountered. For example, freeze-dried formulations 
may have superior stability but can be more 
complicated for users, with increased potential for 
error. Packaging and shipping costs may be higher for 
freeze-dried vaccines, and they can require more 
storage space.
Heat Stability vs. Vaccine Format
• Heat stabilization technologies may yield superior 
product formats. For example:
– Spray drying can yield free-flowing powders of 
controlled particle size, facilitating aerosol delivery, dry 
powder jet injection, coated microneedles, and erodible 
implants.
– Freeze drying can be used to create fast-dissolving 
tablets for convenient oral delivery.
Lesson 7: Products with enhanced 
stability can benefit both vaccine 
producers and purchasers.
Stable Vaccines: 
Benefits to Vaccine Producers
• Enhance product features and 
competitiveness.
• Potentially reduce costs through 
bulk production efficiencies.
• Reduce risk of recalls when the 
cold chain is breached during 
shipment.
• Decrease shipping and storage 
costs.
Stable Vaccines: 
Benefits to Purchasers and End Users
• Widen the reach of immunization.
• Improve vaccine effectiveness.
• Reduce vaccine wastage and cost.
Levin, et al. Vaccine. 2007;25:9645-9657.




• Many stabilization technologies exist to protect 
technologies from freeze and heat damage.
• Heat stabilization requires a customized approach, with 
variable results.
• In general, it is easier and less expensive to address 
vaccine stability during initial development, but 
reformulation of existing vaccines is sometimes 
warranted.
• Many existing vaccines could be stored at controlled 
temperatures higher than the traditional cold chain, but 
additional studies and policy changes are needed.
• Thermostable vaccines can benefit producers as well 
as purchasers and end users.
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